百奥泰: 百奥泰 2025年第二次临时股东会会议资料

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order during the meeting [1][2] - The meeting will include discussions on several key proposals, including changes to the company's registered address and the signing of a licensing agreement for BAT1806 (Tocilizumab) [7][9][11] Meeting Procedures - Attendees must verify their identity upon arrival and sign in to confirm their participation [1][2] - Shareholders and their representatives have the right to speak, inquire, and vote during the meeting, but must register to speak in advance [2][3] - Voting will be conducted through both on-site and online methods, with results announced after the meeting [3][5] Agenda Items - Proposal 1: Change of registered address and amendment of the company's articles of association, with the new address being "18 Spiral Second Road, International Biological Island, Guangzhou" [7][9] - Proposal 2: Signing a licensing and commercialization agreement for BAT1806 (Tocilizumab) with STADA Arzneimittel AG, with a total transaction amount of up to €136 million [10] - Proposal 3: Establishment of a remuneration management system for directors and senior management to enhance corporate governance [11][12]